The present work was done to study the trophic effect of human recombinant erythropoietin on the developing small bowel in neonatal rats. This study was carried out on 24 neonatal rats aged 4-5 days, weighing 40-60gm, and 
INTRODUCTION
Erythropoietin (Epo) is a glycoprotein with a true hormonal structure which is located in the alphaglobulin of the plasma (1) . It is one of the growth factors that have a positive effect on haematopoietic growth and wound healing (2) . Epo is present in human milk, amniotic fluid (3) , bone marrow and spleen (4) . Epo receptors are present in the intestinal villi of developing humans and rats (5) . These Epo receptors appear to be functional, as recombinant Epo increases the cell migration and decreases apoptotic death following damage and has trophic effects on cultured gastric mucosal cells (6) . The Epo receptors are present on enterocytes, and they are a readily accessible source of its ligand which is available to the fetus and breast fed neonates (5) . The possible physiological roles of Epo in the developing bowel are systemic erythropoietic effect and local effect (7) . Epo might have local effect on developing bowel, as rats treated with parenteral recombinant Epo prior to a surgical anastomosis showed improved healing with increased strength of the anastomosis (7) . Also, infants who received recombinant Epo for anaemia of prematurity showed, decreased incidence of necrotising enterocolitis compared to infants who did not receive recombinant Epo (9) . The aim of the present work was to study the trophic effect of human recombinant erythropoietin on the developing small bowel of neonatal rats.
MATERIALS & METHODS
24 neonatal rats of 4-5 days age, and weighing 40-60gm, were kept with their mothers in containers containing dust free maize cob bedding and at conditioned temperature at 37 o C. The rats were fed freely from their mothers, which were fed by milk and bread and had free water access with regular perfect cleaning. The neonatal rats were divided into four groups each containing 6 rats. Groups (1): is the control group, administrated 1/2 ml saline by small intra-gastric tube (PE-10) from (Sigma) for one week. Groups (2): administrated enterally by human recombinant Epo (Amoun) in a dose of 200u/kg/day (7) by intragastric tube for one week. intraperitonealy for one week .
Group
At the end of the experimental period, rats were weighed, and blood was collected by cardiac puncture for estimation of: Haematocrit value% measured by the method of Juul (7) . Erythropoietin concentration was measured by duplication with quanntikine IVP ELISA kit (R&D systems. Minneapolis) which based on the Double-Antibody Sandwich Method with the use of monoclonal antibody by the method of Jazayeri et al.
(10) .
Histological examination:
The animals were sacrificed, dissected. The abdomen was opened, the entire small intestine was removed and length was measured. Sections of the ilium were taken, kept in formalin and fixed in paraffin blocks for histological examination.
Statistical analysis
All results were expressed as mean values + standard deviation (SD). Mean values of different groups were compared using one way analysis of variance. The least significant different mean values, P< 0.05 was accepted to denote a significant difference.
RESULTS
The results of the present work are shown in 
Histological examination
Examination of ilium showed increased surface area of the ilial mucosa, and increased length of the ilial villi in neonatal rats administrated enteral and parenteral human recombinant Epo, (Figures 5-7). 
DISCUSSION
Erythropoietin (Epo) is a haematopoietic growth factor with a true hormonal structure, located in the alpha globulin fraction of plasma, and has a molecular weight of 46.000 Kilo daltons (2) .Like growth hormone, it is also a member of the haematopoietic super family which consists of growth hormone, Epo, granulocyte and macrophage colony stimulating factors and interleukin 3,4,6,7. All of them have similarities in their receptor structure, and cross-reactivity between certain growth factors may be exist (11) . Epo is produced mainly in the kidneys and to a lesser extent in the liver . It is possible that, the effects of human recombinant Epo on small bowel would be route dependent. The results showed that Epo whether given enterally or parenterally, had a trophic effect on small bowel, but the enterally administrated Epo had a greater effect than parenterally Epo on small bowel length , and associated with increase in villus length and mucosal surface area, which is more pronounced in the ilium (23) . The mechanism of increase of growth may be due to increase in cell turnover and increase in cell migration (24) . Moreover, Epo receptors are present on a variety of non haematopoietic cell types, including enterocytes, endothelial cells, smooth muscle cells and neurons which are present in the developing bowel (25) . It is possible that Epo acts as a trophic factor on one or more of these cell types during growth and development (26) .
Conclusion and Recommendation:
It is concluded that, parenteral administration of human recombinant Epo has haematopoietic and trophic effect on small bowel. 
